Compare Stocks: AUPH, ALKS, IBRX, and RYTM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$48.87 +1.1%	$50.50	$25.17 ▼ $55.67	$8.20B	0.34	2.17 million shs	1.30 million shs
AUPH Aurinia Pharmaceuticals	$16.57 -0.5%	$15.95	$10.34 ▼ $19.25	$2.20B	1.42	1.25 million shs	686,273 shs
IBRX ImmunityBio	$7.58 -2.7%	$7.78	$1.95 ▼ $12.43	$8.03B	0.03	22.41 million shs	5.61 million shs
RYTM Rhythm Pharmaceuticals	$111.44 +1.3%	$108.03	$74.50 ▼ $122.20	$7.64B	1.92	779,687 shs	400,563 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	-1.49%	-8.62%	+31.33%	+62.45%
AUPH Aurinia Pharmaceuticals	0.00%	+7.63%	+8.47%	+9.40%	+35.70%
IBRX ImmunityBio	0.00%	+2.91%	+9.72%	+7.89%	+237.23%
RYTM Rhythm Pharmaceuticals	0.00%	-4.75%	+7.74%	+25.23%	+6.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$48.87 +1.1%	$50.50	$25.17 ▼ $55.67	$8.20B	0.34	2.17 million shs	1.30 million shs
AUPH Aurinia Pharmaceuticals	$16.57 -0.5%	$15.95	$10.34 ▼ $19.25	$2.20B	1.42	1.25 million shs	686,273 shs
IBRX ImmunityBio	$7.58 -2.7%	$7.78	$1.95 ▼ $12.43	$8.03B	0.03	22.41 million shs	5.61 million shs
RYTM Rhythm Pharmaceuticals	$111.44 +1.3%	$108.03	$74.50 ▼ $122.20	$7.64B	1.92	779,687 shs	400,563 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	0.00%	-1.49%	-8.62%	+31.33%	+62.45%
AUPH Aurinia Pharmaceuticals	0.00%	+7.63%	+8.47%	+9.40%	+35.70%
IBRX ImmunityBio	0.00%	+2.91%	+9.72%	+7.89%	+237.23%
RYTM Rhythm Pharmaceuticals	0.00%	-4.75%	+7.74%	+25.23%	+6.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.72	Moderate Buy	$54.56	11.65% Upside
AUPH Aurinia Pharmaceuticals	2.50	Moderate Buy	$17.67	6.62% Upside
IBRX ImmunityBio	2.71	Moderate Buy	$14.20	87.34% Upside
RYTM Rhythm Pharmaceuticals	2.78	Moderate Buy	$142.44	27.82% Upside

Current Analyst Ratings Breakdown

Latest AUPH, ALKS, IBRX, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/20/2026	AUPH Aurinia Pharmaceuticals	Bloom Burton Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/12/2026	AUPH Aurinia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
8/7/2026	ALKS Alkermes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	AUPH Aurinia Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$15.00 ➝ $16.00
8/7/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$145.00 ➝ $146.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$154.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/5/2026	RYTM Rhythm Pharmaceuticals	National Bank Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$160.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$142.00 ➝ $143.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$141.00 ➝ $155.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$155.00 ➝ $160.00

(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.48B	5.55	$1.69 per share	28.86	$11.02 per share	4.43
AUPH Aurinia Pharmaceuticals	$283.05M	7.79	$1.01 per share	16.43	$4.41 per share	3.76
IBRX ImmunityBio	$165.79M	48.46	N/A	N/A	($0.51) per share	-14.86
RYTM Rhythm Pharmaceuticals	$239.92M	31.83	N/A	N/A	$2.08 per share	53.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	128.61	203.63	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
AUPH Aurinia Pharmaceuticals	$287.20M	$2.29	7.24	19.27	N/A	100.84%	26.11%	19.89%	11/3/2026 (Estimated)
IBRX ImmunityBio	-$351.40M	-$0.97	N/A	N/A	N/A	-598.55%	N/A	-51.65%	11/3/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)

Latest AUPH, ALKS, IBRX, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AUPH Aurinia Pharmaceuticals	$0.24	$0.28	+$0.04	$0.28	$80.45 million	$58.57 million
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.08	-$0.22	-$0.14	-$0.22	$49.70 million	$51.24 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
AUPH Aurinia Pharmaceuticals	0.07	5.42	4.97
IBRX ImmunityBio	N/A	5.72	5.70
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
AUPH Aurinia Pharmaceuticals	36.83%
IBRX ImmunityBio	8.58%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
AUPH Aurinia Pharmaceuticals	10.40%
IBRX ImmunityBio	66.10%
RYTM Rhythm Pharmaceuticals	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
AUPH Aurinia Pharmaceuticals	300	133.05 million	119.21 million	Optionable
IBRX ImmunityBio	590	1.06 billion	359.28 million	Optionable
RYTM Rhythm Pharmaceuticals	140	68.53 million	64.49 million	Optionable

AUPH, ALKS, IBRX, and RYTM Headlines

Recent News About These Companies

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

August 24 at 8:00 AM | globenewswire.com

6,156,902 Shares in Rhythm Pharmaceuticals, Inc. $RYTM Purchased by BlackRock Inc.

August 24 at 3:35 AM | marketbeat.com

Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can

August 23 at 6:00 PM | fool.com

Deutsche Bank AG Purchases New Position in Rhythm Pharmaceuticals, Inc. $RYTM

August 23 at 3:43 AM | marketbeat.com

Blue Owl Capital Holdings LP Invests $6.82 Million in Rhythm Pharmaceuticals, Inc. $RYTM

August 21 at 3:35 AM | marketbeat.com

Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise

August 18, 2026 | seekingalpha.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Joseph Shulman Sells 5,079 Shares

August 18, 2026 | insidertrades.com

Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Sells 5,079 Shares of Stock

August 17, 2026 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Alastair Garfield Sells 7,763 Shares

August 17, 2026 | marketbeat.com

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

August 17, 2026 | globenewswire.com

Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts

August 17, 2026 | marketbeat.com

Jennifer Kayden Lee Sells 75,834 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

August 16, 2026 | americanbankingnews.com

Yann Mazabraud Sells 57,000 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

August 16, 2026 | americanbankingnews.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Yann Mazabraud Sells 57,000 Shares of Stock

August 15, 2026 | insidertrades.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Yann Mazabraud Sells 57,000 Shares

August 14, 2026 | marketbeat.com

Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Sells 75,834 Shares of Stock

August 14, 2026 | marketbeat.com

Dimensional Fund Advisors LP Sells 12,867 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

August 14, 2026 | marketbeat.com

Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?

August 12, 2026 | benzinga.com

Bank of America Corp DE Grows Stake in Rhythm Pharmaceuticals, Inc. $RYTM

August 12, 2026 | marketbeat.com

Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript

August 11, 2026 | finance.yahoo.com

Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in ...

August 11, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AUPH, ALKS, IBRX, and RYTM Company Descriptions

Alkermes NASDAQ:ALKS

$48.87 +0.54 (+1.12%)

Closing price 04:00 PM Eastern

Extended Trading

$48.86 0.00 (-0.01%)

As of 04:52 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Aurinia Pharmaceuticals NASDAQ:AUPH

$16.57 -0.08 (-0.48%)

Closing price 04:00 PM Eastern

Extended Trading

$16.59 +0.02 (+0.12%)

As of 05:27 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

ImmunityBio NASDAQ:IBRX

$7.58 -0.21 (-2.70%)

Closing price 04:00 PM Eastern

Extended Trading

$7.54 -0.04 (-0.46%)

As of 05:54 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Rhythm Pharmaceuticals NASDAQ:RYTM

$111.44 +1.44 (+1.31%)

Closing price 04:00 PM Eastern

Extended Trading

$111.52 +0.08 (+0.07%)

As of 04:29 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AUPH, ALKS, IBRX, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AUPH, ALKS, IBRX, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AUPH, ALKS, IBRX, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AUPH, ALKS, IBRX, and RYTM Company Descriptions

Alkermes NASDAQ:ALKS

Aurinia Pharmaceuticals NASDAQ:AUPH

ImmunityBio NASDAQ:IBRX

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AUPH, ALKS, IBRX, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AUPH, ALKS, IBRX, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AUPH, ALKS, IBRX, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AUPH, ALKS, IBRX, and RYTM Company Descriptions

Alkermes NASDAQ:ALKS

Aurinia Pharmaceuticals NASDAQ:AUPH

ImmunityBio NASDAQ:IBRX

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools